EQRx, Inc. (EQRX): Price and Financial Metrics
EQRX Price/Volume Stats
Current price | $2.34 | 52-week high | $5.55 |
Prev. close | $2.39 | 52-week low | $1.58 |
Day low | $2.32 | Volume | 16,554,600 |
Day high | $2.42 | Avg. volume | 3,297,760 |
50-day MA | $2.25 | Dividend yield | N/A |
200-day MA | $2.05 | Market Cap | 1.14B |
EQRX Stock Price Chart Interactive Chart >
EQRx, Inc. (EQRX) Company Bio
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase I clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
EQRX Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | N/A |
1-year | N/A |
3-year | -76.48% |
5-year | N/A |
YTD | N/A |
2023 | 0.00% |
2022 | -63.93% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...